Generic Fanapt Availability
FANAPT (iloperidone - tablet;oral)
Manufacturer: VANDA PHARMS INC
Approval date: May 6, 2009
Strength(s): 12MG, 1MG [RLD], 2MG, 4MG, 6MG, 8MG, 10MG
Has a generic version of Fanapt been approved?
No. There is currently no therapeutically equivalent version of Fanapt available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fanapt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods for the administration of iloperidone
Issued: November 19, 2013
Assignee(s): Vanda Pharmaceuticals, Inc.
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.Patent expiration dates:
- November 2, 2027✓
- November 2, 2027
Prediction of QT prolongation based on SNP genotype
Issued: February 18, 2014
Assignee(s): Vanda Pharmaceuticals, Inc.
The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.Patent expiration dates:
- August 31, 2030✓
- August 31, 2030
Patent 8,999,638Patent expiration dates:
- October 28, 2030✓
- October 28, 2030
Patent 9,072,742Patent expiration dates:
- January 16, 2031✓
- January 16, 2031
Patent 9,074,254Patent expiration dates:
- December 28, 2031✓
- December 28, 2031
Patent 9,074,255Patent expiration dates:
- December 17, 2030✓
- December 17, 2030
Patent 9,074,256Patent expiration dates:
- February 10, 2031✓
- February 10, 2031
Patent 9,138,432Patent expiration dates:
- September 30, 2025✓
- September 30, 2025
Patent 9,157,121Patent expiration dates:
- April 5, 2030✓
- April 5, 2030
Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Issued: July 18, 2006
Inventor(s): Strupczewski; Joseph T. & Helsley; Grover C. & Chiang; Yulin & Bordeau; Kenneth J. & Glamkowski; Edward J.
Assignee(s): Aventis Pharmaceuticals Inc.
Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Patent expiration dates:
- November 15, 2016✓✓✓
- November 15, 2016
More about Fanapt (iloperidone)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|